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Abstract
Introduction: Outbreaks of syphilis have been described among HIV-infected men who have sex with men (MSM) in Western
communities, whereas reports in Asian countries are limited. We aimed to characterize the incidence and temporal trends of
syphilis among HIV-infected MSM compared with HIV-infected non-MSM in Asian countries.
Methods: Patients enrolled in the TREAT Asia HIV Observational Database cohort and with a negative non-treponemal test
since enrolment were analyzed. Incidence of syphilis seroconversion, defined as a positive non-treponemal test after previously
testing negative, was evaluated among patients at sites performing non-treponemal tests at least annually. Factors associated
with syphilis seroconversion were investigated at sites doing non-treponemal testing in all new patients and subsequently
testing routinely or when patients were suspected of having syphilis.
Results: We included 1010 patients from five sites that performed non-treponemal tests in all new patients; those included
had negative non-treponemal test results during enrolment and subsequent follow-ups. Among them, 657 patients were from
three sites conducting regular non-treponemal testing. The incidence of syphilis seroconversion was 5.38/100 person-years
(PY). Incidence was higher in MSM than non-MSM (7.64/100 PY vs. 2.44/100 PY, pB0.001). Among MSM, the incidence
rate ratio (IRR) for every additional year from 2009 was 1.19 (p0.051). MSM status (IRR 3.48, 95% confidence interval (CI)
1.886.47), past syphilis diagnosis (IRR 5.15, 95% CI 3.697.17) and younger age (IRR 0.84 for every additional 10 years, 95% CI
0.7060.997) were significantly associated with syphilis seroconversion.
Conclusions: We observed a higher incidence of syphilis seroconversion among HIV-infected MSM and a trend to increasing
annual incidence. Regular screening for syphilis and targeted interventions to limit transmission are needed in this population.
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Introduction
After the development of penicillin, the number of syphilis
cases fell to its lowest level in 2000 in the United States, from
20.3 cases per 100,000 people to 2.9 cases per 100,000 people.
However, the overall number of new infection cases gradually
increased after the early 2000s to 6.3 cases per 100,000 people
in 2014 [1]. The World Health Organization reported that
there were 10.6 million global new syphilis cases in 2008 [2].
Syphilis is also considered to be an significant problem in other
specific areas, as more than a quarter of new cases of syphilis
and other sexually transmitted infections have occurred in the
Western Pacific region, including South Korea, Japan, Taiwan,
China,Thailand, the Philippines and Australia [2]. Patientswere
predominantly male, and one surveillance reported that more
than 60% of male patients were men who have sex with men
(MSM) [1].
The estimated HIV prevalence in Asia is low (0.1% in East
Asia and 0.3% in Southeast Asia) compared with other regions
such as North America (0.5%) and Africa (4.7%) [3]. However,
unlike the global decreasing trend of HIV prevalence,
the estimated number of new cases has increased in
East Asia since 2001 [3]. With regard to the transmission
route, intravenous drug use, contaminated blood products
and heterosexual contact initially played an important role in
HIV transmission in Asian countries. However, the epidemic
has recently changed, and the transmission of HIV among
MSM has become a major threat in many Asian countries [4].
HIV and Treponema pallidum share similar routes of
transmission. Syphilitic ulcers are known to disrupt the
mucosal barriers, facilitating the passage of HIV [5,6]. Syphilis
is also associated with a decrease in CD4 T lymphocyte
and an increase in HIV viral load in co-infected patients [7,8].
Some reports suggest that atypical or severe forms of syphilis
are more frequent, and the course of syphilis more rapid, in
HIV-infected patients [911].
In the 1990s, the incidence of syphilis in HIV-infected
patients fell significantly, with enhanced screening, education
and behavioural changes [12,13]. However, a re-emergence of
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syphilis was reported in the 2000s in industrialized countries,
especially among MSM [1418]. In Western settings, a
syphilis incidence of 2.9 to 6.2 per 100 PY has been reported
in HIV-infected MSM [1922]. The reasons for this resurgence
of syphilis are complex, involving changes in risk behaviour
and awareness of the need for testing [14,18,2325].
Recently, the morbidity and mortality of HIV-infected patients
has significantly decreased with prolonged life expectancy.
This has enabled an increase in sexual activities, including
risky sexual behaviours and serosorting of sexual partners
among MSM [16,26,27]. Previous studies have reported that
33 to 52% of syphilis infections can be asymptomatic, creating
additional challenges for diagnosis and stopping transmission
[19,28,29]. To enhance identification and facilitate treatment
in the context of concomitant HIV, US and European guide-
lines for management of HIV infection recommend routine
screening of syphilis at least yearly among MSM [3032].
However, routine screening of syphilis is limited in Asia.
Many countries in the region have limited healthcare
resources and the high false-positive rate of non-treponemal
testing used for syphilis screening may make this approach
unsuitable in this setting [33,34]. Furthermore, data about
rates of syphilis in Asian are inconsistent. There have been
several reports of increasing syphilis co-infection among
HIV-infected patients in Asian countries [4,35,36], while
another study in Thailand found that only 1.7% of patients
screened routinely had syphilis, suggesting the possible
reduced importance of routine screening in this region [33].
As data remain limited, we aimed to determine trends in
incidence and predictors of syphilis seroconversion, particu-
larly among MSM compared to non-MSM, in a regional cohort
of HIV-infected patients in Asia.
Methods
Study sites and population
The TREAT Asia HIV Observational Database (TAHOD) is a
prospective, observational cohort study of HIV-infected pa-
tients enrolled from 21 clinical sites in 12 countries in the
AsiaPacific region, the details of which have been previously
described [37]. Briefly, each site enrols 100 to 450 HIV-infected
patients, both treated and untreated with antiretroviral
therapy (ART). Data are collected according to a common
protocol. On recruitment, all available retrospective data
prior to enrolment in TAHOD are collected. Prospective data
are biannually transferred to a central data management
and biostatistical analysis centre. Institutional review board
approvals are obtained at all participating sites, the data
management and analysis centre (Kirby Institute, University of
New South Wales, Sydney, Australia), and the coordinating
centre (TREAT Asia/amfAR, Bangkok, Thailand). Patients pro-
vide written informed consent to participate in TAHOD, where
required by local institutional review boards (IRBs).
Among the participating sites, five (one each in South
Korea, Taiwan, Hong Kong, Japan and the Philippines) conduct
syphilis testing of all new patients. All five countries have
only one contributing site each. Three of these sites (in
South Korea, Taiwan and Hong Kong) perform routine testing
for syphilis at least yearly, whereas the other two sites
perform testing only when patients are symptomatic or
suspected of having syphilis (Table 1). We investigated the
incidence of syphilis seroconversion at sites that test patients
for syphilis at least annually (n3) and described factors
associated with syphilis seroconversion at sites that test
all new patients (n5). Patients with a negative Venereal
Disease Research Laboratory (VDRL) test or rapid plasma
regain (RPR) test after enrolment into TAHOD were eligible for
inclusion in the analysis.
Study variables and definitions
The study end point was syphilis seroconversion, defined as a
positive VDRL or RPR test after previously testing negative
during TAHOD enrolment. VDRL and RPR tests appear to be
accurate and reliable for diagnosis and monitoring treatment
response in most HIV-infected patients [38]. The sensitivity of
the non-treponemal test is known to be 78 to 86% in primary
syphilis and 100% in secondary syphilis, with 98% specificity
[38,39]. Either VDRL or RPR tests were performed on patients
according to the testing policy of each site. The positive VDRL
and PRP tests included the results of both qualitative and
quantitative tests. Study variables included age, sex, ethni-
city, mode of HIV exposure, hepatitis B and C serology,
history of prior AIDS diagnosis, CD4 cell count, HIV viral load,
highly active antiretroviral therapy (HAART) regimen and past
history of having positive VDRL or RPR test prior to baseline.
Table 1. Syphilis testing practices at participating study sites
Site country
Number of
contributing
patients
Testing
new
patients
Testing symptomatic
or suspected patients
Regular
screening
Increased test
frequency for any
patients?
Median number of
reported tests per
patient per year (IQR)
South Korea 177 Yes Yes Every six months No 2.07 (1.552.65)
Taiwan 343 Yes Yes Minimum every
12 months
Every six months for
those subjectively
assessed to be at high risk
1.17 (0.072.18)
Hong Kong 137 Yes Yes Minimum every
12 months
Every six months for
MSM
1.84 (0.152.80)
Japan 83 Yes Yes No No 0.54 (0.241.13)
Philippines 270 Yes Yes No No 0.62 (0.400.84)
IQR, interquartile range; MSM, men who have sex with men.
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Variables were measured at baseline. Baseline was consid-
ered as the date of first negative VDRL or RPR test during
TAHOD enrolment.
Statistical analysis
Patients were only censored at the first positive syphilis test
and not able to contribute more than one outcome. Follow-up
was censored at the last available clinic visit date without
a record of seroconversion. The total and annual incidence
of syphilis seroconversion was evaluated overall and by MSM
status (MSM/non-MSM). Trends in syphilis incidence were
evaluated by univariate Poisson regression. Predictors of
syphilis seroconversion were evaluated by Poisson regression
adjusted for study site. In the analysis of predictors of syphilis
seroconversion, covariates significant in the univariate model
at pB0.10 were chosen for inclusion in the multivariate
model. Covariates with pB0.05 in the final multivariatemodel
were considered statistically significant. All models were
adjusted for each study site, although the incidence rate ratio
(IRR) for each site is not shown. Missing categories were
included in the models; however, the IRRs are not reported.
Stata statistical software (version 12.1; StataCorp, College
Station, TX, USA) was used for all statistical analyses.
Results
From September 2003 to March 2014, data from 2135
patients receiving HIV care at one of the five sites were
available for this analysis. Overall, 1047 (49.0%) patients had
a negative VDRL or RPR test during enrolment, and 1010
(96.4%) had subsequent follow-up testing data. Among the
three sites that routinely tested for syphilis, 1359 patients
were enrolled in TAHOD, 691 (50.8%) had a negative VDRL or
RPR result during enrolment and 657 (95.1%) had subsequent
follow-up data. The demographics and characteristics of all
patients (n1010) and those considered for the incidence
analysis (n657) are shown in Table 2. Both groups were
predominantly male. Median age, proportions having prior
AIDS and using HAART at the time of syphilis seroconversion
were similar among both groups. Homosexual contact was the
most common mode of HIV exposure (63.0% in all patients
and 65.4% in the incidence group). The median baseline
CD4 cell count was 393 cells/mm3 (interquartile range (IQR)
253551) among the overall group of patients and 410
cells/mm3 (IQR 259561) in the incidence group. Twenty
percent of the overall group and 24.7% of the incidence group
had a history of syphilis infection before enrolment.
Incidence analysis
During the study period, there were a total of 127 cases of
syphilis seroconversion in the incidence group. The total
follow-up duration was 2359 person-years (PY) and the
median follow-up time per patient was 2.92 (IQR 1.085.69)
years. A median of 1.59 (IQR 0.802.54) VDRL or RPR tests per
patient per year were performed. The overall incidence of
syphilis seroconversion was 5.38 (95% confidence interval
(CI) 4.526.41) per 100 PY.When assessed by MSM status, the
incidence of seroconversion was 2.44 (95% CI 1.653.61) per
100 PY among non-MSM and 7.64 (95% CI 6.299.28) per 100
PY among MSM (pB0.001).
Over the study period, the rate of syphilis seroconversion
was lowest in 2003 to 2004 at 2.96/100 PYand tended to show
an increasing trend over time (Figure 1). Incidence was 7.48/
100 PY in the period from 2013 to 2014. In particular, Figure 1
indicates a recent increase from 2009 with a visually ascending
trend in annual incidence. From 2009 onwards, the univariate
IRR for every additional year was 1.14 (95% CI 0.981.32,
p0.091). Yearly change in incidence was also evaluated
byMSM status (Figure 2). In any given year, incidence was con-
sistently higher among the MSM patients. In this group, in-
cidence reached a peak value of 10.77/100 PY in 2013 to 2014.
Table 2. Baseline characteristics
Total patients
Incidence
subgroup
Factors (n1010) (n657)
Male, n (%) 933 (92.4) 621 (94.5)
Age (years), n (%)
530 235 (23.3) 138 (21.0)
3140 335 (33.2) 223 (33.9)
4150 276 (27.3) 181 (27.5)
50 164 (16.2) 115 (17.5)
Median (IQR) 38.2 (30.345.6) 38.5 (31.145.7)
Ethnicity, n (%)
Asian 1003 (99.3) 653 (99.4)
Caucasian 5 (0.5) 4 (0.6)
Other 2 (0.2) 0 (0.0)
HIV exposure, n (%)
Heterosexual 230 (22.8) 136 (20.7)
MSM 636 (63.0) 430 (65.4)
Injecting drug use 11 (1.1) 10 (1.5)
Other 133 (13.2) 81 (12.3)
Prior AIDS diagnosis, n (%) 354 (35.0) 235 (35.8)
CD4 cell count (cells/mm3), n (%)
]500 301 (29.8) 215 (32.7)
350499 248 (24.6) 171 (26.0)
200349 236 (23.4) 152 (23.1)
B200 154 (15.2) 95 (14.5)
Median (IQR) 393 (253551) 410 (259561)
HIV viral load (copies/ml), n (%)
B400 546 (54.1) 439 (66.8)
]400 258 (25.5) 171 (26.0)
Median (IQR) 49 (393410) 49 (39950)
Median years after HIV
diagnosis (IQR)
3.59 (1.56.6) 3.54 (1.66.6)
Using HAART at baseline, n (%) 887 (87.8) 570 (86.8)
Positive HBsAg, n (%) 101 (11.9) 70 (13.4)
Positive hepatitis C antibody,
n (%)
43 (5.4) 34 (6.0)
Past syphilis diagnosis, n (%) 202 (20.0) 162 (24.7)
IQR, interquartile range; MSM, men who have sex with men;
HAART, highly active antiretroviral therapy; HBsAg, hepatitis B
surface antigen.
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The univariate IRR for every additional year from2009 onwards
was 1.19 in MSM (95% CI 1.001.41, p0.051) and 0.97
(95% CI 0.711.31, p0.838) in non-MSM.
Factors associated with syphilis seroconversion
Factors associated with syphilis seroconversion among all
patients are shown in Table 3. In the multivariate analysis, HIV
exposure via MSM contact (IRR 3.48 vs. heterosexual, 95% CI
1.886.47, pB0.001), past diagnosis of syphilis (IRR 5.15 vs.
none, 95% CI 3.697.17, pB0.001) and younger age (IRR 0.84
for every additional 10 years, 95% CI 0.7060.997, p0.047)
were significantly associated with syphilis seroconversion.
Discussion
Data about syphilis incidence from Asian countries have been
limited and have shown inconsistent results [33,35,36,40].
Most studies in Asia have only reported prevalence figures
among HIV-infected patients or syphilis incidence in MSM
regardless of HIV infection status. In a single centre study in
Thailand, the prevalence of syphilis in HIV-infected patients
was reported as 1.7% [33]. However, in that study, only 14.6%
of the patients had reported homosexual contact risk, and
the frequency of sexual contact may have further influenced
the results (55.6% of the overall patients and 84% of MSM
reported no recent sexual intercourse).
In our study, the overall incidence of syphilis seroconver-
sion was higher than expected based on previous reports,
which may be related to the higher proportion of MSM in our
study population. Syphilis seroconversion was more frequent
in the MSM group, and yearly incidence showed an
increasing trend after 2009.
There are several possible reasons for the increases in
syphilis seroconversions. Multiple sexual partners, use of
drugs like methamphetamine or meeting partners over the
Internet have been shown to increase risks of syphilis
infection in HIV patients [41,42]. Serial data suggests that
risky behaviours are increasing in some HIV-infected MSM
populations where syphilis rates are rising [26,43,44]. In
one study from California, the proportion of HIV-infected
MSM having 10 or more sexual partners or engaging in
unprotected anal intercourse in the previous six months
was reported to have increased in the early 2000s [45]. In
addition, it has been shown that MSM can select their sexual
partners or behaviours on the basis of their HIV infection
status, in a practice known as serosorting [4649]. This may
be used to avoid the risk of transmitting HIV to an HIV-
uninfected partner but could be associated with the risk of
sexually transmitted infections including syphilis because
risky sexual behaviour can be more common among HIV-
infected MSM [46,5052].
In many countries, preventive interventions for HIV and
syphilis among MSM have primarily targeted the HIV
uninfected [46,53]. However, the high incidence of syphilis
among HIV-infected MSM in other contexts and observed in
our cohort suggests that additional efforts are needed to
support prevention within the MSM community.
In addition to reducing risky behaviours, another key
component of a public health strategy to address syphilis in
8
7
6
5
4
3
2
1
0
2003/04
Year 2003/04
2
67.6
2.96
0.73–11.83
Cases
PY*
Incidence+
95% CI++
* PY, person-years; + cases per 100 person-years; ++ CI, confidence interval
2005
2005
6
104.3
5.75
2.59–12.81
2006
2006
6
132.2
4.54
2.04–10.10
2007
5
166.9
3.00
1.25–7.20
2008 2009 2010
14
299.4
4.68
2.77–7.90
2011
18
329.5
5.46
3.44–8.67
2012 2013/14
29
387.6
7.48
5.20–10.77
20
358.6
5.58
3.60–8.64
12
266.6
4.50
2.56–7.92
15
240.3
6.24
3.76–10.35
2007 2008 2009 2010 2011 2012 2013/14
In
ci
de
nc
e 
pe
r 1
00
 p
at
ie
nt
-y
ea
rs
 o
f f
ol
lo
w-
up
Figure 1. Incidence of syphilis seroconversion among HIV-infected patients by year (n657).
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HIV-infected individuals is early detection and prompt
treatment. Current US and European guidelines recom-
mend at least annual screening for sexually transmitted
infections, including syphilis, in sexually active HIV-infected
patients [30,31]. In our cohort, only 3 of 21 sites performed
regular syphilis screening on all or even a subset of patients.
Our findings indicate that regional health programmes may
need to consider implementing routine screening in those
with HIV.
There were several limitations to our study. Firstly, we
considered that syphilis seroconversion defined as a newly
positive VDRL or RPR test represented syphilis infection.
Current guidelines recommend performing both treponemal
tests and non-treponemal tests for syphilis diagnosis [31,54].
Non-treponemal tests can have high rates of false positivity,
which could overestimate the incidence of syphilis [55].
Secondly, the scope of data collection in our observational
cohort did not allow for an assessment of clinical manifesta-
tions or of titres of non-treponemal tests; therefore, we
could not establish whether there was a fourfold increase in
the VDRL or RPR titre in order to define a syphilis infection
among those with a history of syphilis and clinical diagnosis,
such as primary or secondary syphilis. Similarly we were
unable to correlate sexual behaviour information beyond
the reported HIV exposure category or history of other
sexually transmitted infections to syphilis seroconversions.
In addition, only 5 of the 21 sites in our cohort conducted
routine syphilis screening and were included in our analysis,
and 4 of these were in high-income economies, preventing
extrapolation to low- and middle-income settings.
Despite these limitations, this is the first multicentre study
investigating syphilis infection among HIV-infected patients in
Asia, where the epidemiology of HIV and syphilis and socio-
economic status differ from Western settings. Understanding
local disease epidemics and recent trends of incidence is
essential for prevention and interventions.
Conclusions
The high incidence of syphilis seroconversion observed in our
study, especially among HIV-infected MSM, may represent
high rates of transmissions and ongoing risky sexual beha-
viours, and it highlights the need for targeted intervention
and regular syphilis screening in this population.
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Table 3. Factors associated with syphilis seroconversion among HIV-infected patients (n1010)
Baseline risk factor Univariate IRR (95% CI) p Multivariate IRR (95% CI) p
HIV exposure
Heterosexual 1 1
MSM 5.50 (2.9610.22) B0.001 3.48 (1.886.47) B0.001
Injecting drug use 1.61 (0.2112.52) 0.649
Other 3.39 (1.577.34) 0.002 2.50 (1.165.42) 0.02
Past syphilis diagnosis
No 1 1
Yes 6.06 (4.378.39) B0.001 5.15 (3.697.17) B0.001
Age, every 10-year increase 0.83 (0.700.98) 0.029 0.84 (0.711.00) 0.047
Sex
Male 1
Female 0.07 (0.010.54) 0.01
Prior AIDS diagnosis
Not known 1
Yes 0.76 (0.541.09) 0.134
CD4 cell count (cells/mm3)
]500 1
350499 1.14 (0.751.73) 0.549
200349 0.94 (0.611.44) 0.775
B200 1.19 (0.711.98) 0.515
HIV viral load (copies/ml)
B400 1
]400 0.94 (0.651.36) 0.742
Time after HIV diagnosis
Every one-year increase 1.02 (0.981.06) 0.295
Using HAART
Yes 1
No 0.88 (0.561.39) 0.593
HBsAg status
Negative 1
Positive 1.34 (0.842.14) 0.223
Hepatitis C antibody status
Negative 1
Positive 0.95 (0.442.05) 0.888
CI, confidence interval; IRR, incidence rate ratio; MSM, men who have sex with men; HAART, highly active antiretroviral therapy; HBsAg, hepatitis
B surface antigen.
All models were adjusted for study site, though incident rate ratios for sites are not shown.
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